Evidence map›Paper›PMID 30640957›Full record

ArticlePLoS pathogens2019

Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes.

Krishna C Suddala, Christine C Lee, Paul Meraner, Mariana Marin, Ruben M Markosyan, Tanay M Desai, Fredric S Cohen, Abraham L Brass, Gregory B Melikyan

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. From defense to disease: IFITM3 in immunity and Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. FOXP3Nature communications · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Krishna C SuddalaDepartment of Pediatrics, Emory University, Atlanta, GA, United States of America.ORCID 0000-0003-1597-2622
Christine C LeeDepartment of Pediatrics, Emory University, Atlanta, GA, United States of America.ORCID 0000-0003-4540-1628
Paul MeranerDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, United States of America.ORCID 0000-0003-0153-4680
Mariana MarinDepartment of Pediatrics, Emory University, Atlanta, GA, United States of America.
Ruben M MarkosyanRush University Medical Center, Department of Physiology and Biophysics, Chicago, IL, United States of America.
Tanay M DesaiDepartment of Pediatrics, Emory University, Atlanta, GA, United States of America.
Fredric S CohenRush University Medical Center, Department of Physiology and Biophysics, Chicago, IL, United States of America.
Abraham L BrassDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA, United States of America.
Gregory B MelikyanDepartment of Pediatrics, Emory University, Atlanta, GA, United States of America.ORCID 0000-0001-5385-3013
Emory University · USRush University Medical Center · USUniversity of Massachusetts Chan Medical School · US

Funding

The Mechanism of Arenavirus Entry into CellsR01AI053668 · NIAID · UNIVERSITY OF MD BIOTECHNOLOGY INSTITUTE · PI MELIKIAN, GREGORY B · 2003 to 2023
$7.4M
BIOPHYSICS OF PROTEIN-MEDIATED MEMBRANE FUSIONR01GM054787 · NIGMS · UNIVERSITY OF MD BIOTECHNOLOGY INSTITUTE · PI MELIKIAN, GREGORY B · 2000 to 2018
$6.5M
Inhibition of viral entry by interferon-induced proteinsR01AI135806 · NIAID · EMORY UNIVERSITY · PI MELIKIAN, GREGORY B · 2018 to 2022
$1.9M
Molecular Regulation of Fusion: Voltage Dependence and Local Physical InteractionR01GM101539 · NIGMS · RUSH UNIVERSITY MEDICAL CENTER · PI COHEN, FREDRIC S · 2013 to 2016
$1.4M
BIOPHYSICS OF PROTEIN MEDIATED MEMBRANE FUSIONR29GM054787 · NIGMS · RUSH UNIVERSITY MEDICAL CENTER · PI MELIKIAN, GREGORY B · 1996 to 1999
–
NIAID NIH HHS R01 AI053668NIAID NIH HHS R01 AI135806NIGMS NIH HHS R01 GM054787NIGMS NIH HHS R01 GM101539NIGMS NIH HHS R29 GM054787
6 · The paper itself

Abstract

Late endosome-resident interferon-induced transmembrane protein 3 (IFITM3) inhibits fusion of diverse viruses, including Influenza A virus (IAV), by a poorly understood mechanism. Despite the broad antiviral activity of IFITM3, viruses like Lassa virus (LASV), are fully resistant to its inhibitory effects. It is currently unclear whether resistance arises from a highly efficient fusion machinery that is capable of overcoming IFITM3 restriction or the ability to enter from cellular sites devoid of this factor. Here, we constructed and validated a functional IFITM3 tagged with EGFP or other fluorescent proteins. This breakthrough allowed live cell imaging of virus co-trafficking and fusion with endosomal compartments in cells expressing fluorescent IFITM3. Three-color single virus and endosome tracking revealed that sensitive (IAV), but not resistant (LASV), viruses become trapped within IFITM3-positive endosomes where they underwent hemifusion but failed to release their content into the cytoplasm. IAV fusion with IFITM3-containing compartments could be rescued by amphotericin B treatment, which has been previously shown to antagonize the antiviral activity of this protein. By comparison, virtually all LASV particles trafficked and fused with endosomes lacking detectable levels of fluorescent IFITM3, implying that this virus escapes restriction by utilizing endocytic pathways that are distinct from the IAV entry pathways. The importance of virus uptake and transport pathways is further reinforced by the observation that LASV glycoprotein-mediated cell-cell fusion is inhibited by IFITM3 and other members of the IFITM family expressed in target cells. Together, our results strongly support a model according to which IFITM3 accumulation at the sites of virus fusion is a prerequisite for its antiviral activity and that this protein traps viral fusion at a hemifusion stage by preventing the formation of fusion pores. We conclude that the ability to utilize alternative endocytic pathways for entry confers IFITM3-resistance to otherwise sensitive viruses.

Indexed as

A549 CellsAnimalsAntiviral AgentsChlorocebus aethiopsCOS CellsEndosomesHEK293 CellsHost-Pathogen InteractionsHumansInfluenza A virusInterferonsLassa virusMembrane ProteinsOptical ImagingProtein TransportRNA-Binding ProteinsAntiviral AgentsIFITM3 protein, humanInterferonsMembrane ProteinsRNA-Binding Proteins

Identifiers

PMID30640957
PMCPMC6347298
OpenAlexW2910275920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.